Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Riassunto: Agenus annuncia un collocamento privato sottoscritto in eccesso fino a 340 milioni di dollari per portare avanti il trial registrativo ROBBIN sulla combinazione neoadiuvante BOT+BAL nel tumore del colon MSS

Wednesday, July 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. has announced a private placement agreement expected to raise initial gross proceeds of approximately $85 million, with the potential for an additional $255 million through warrant exercises. This funding aims to support the ongoing ROBBIN trial, which focuses on the neoadjuvant combination of BOT and BAL for MSS colon cancer.
Price reaction · baseline $4.97 (2026-07-15T15:14:00.000Z) · hit during market hours · 3 other AGEN headline(s) in the window, move may be shared
day 0 close · peak
+0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus secures significant funding for its clinical trial.
  • The private placement has strong investor interest.
  • Funding will support the advancement of the ROBBIN trial.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
6.2%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
Botensilimab
Phase 1 · Pancreatic Cancer Metastatic

Full Press Release Details

LEXINGTON, Massachussets--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), un leader nell’innovazione dell’immuno-oncologia, oggi ha annunciato di aver siglato un accordo di acquisto di titoli per un collocamento privato che prevede proventi lordi iniziali di circa 85 milioni di dollari, al lordo delle spese associate all’operazione, e fino a ulteriori 255 milioni di dollari in caso di esercizio integrale dei warrant di acquisto. Il testo originale del presente annuncio, redatto nella lingua di par

Frequently Asked Questions

What is the purpose of the ROBBIN trial?

The ROBBIN trial aims to evaluate the neoadjuvant combination of BOT and BAL for treating MSS colon cancer.

How much funding did Agenus secure?

Agenus secured initial gross proceeds of approximately $85 million, with potential for an additional $255 million.

What type of funding arrangement did Agenus announce?

Agenus announced a private placement agreement for funding.

What is the significance of the warrant exercises?

Warrant exercises could increase total funding up to $340 million for the trial.

ShareAdd on Google
Tags: AGEN Viatris Investor Conferences Healthcare Agenus ROBBIN trial MSS colon cancer private placement immuno-oncology
Last updated: Jul 15, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~1 mo
High dilution risk
Lead asset
BotensilimabPhase 1
Pancreatic Cancer Metastatic →

Catalyst track record

+52%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →